Bio Pharma Dive

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 325

Drugs Marketing 325

Pharmaceutical Technology

JULY 6, 2022

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7.

Marketing 324

Marketing Gene Therapy Manufacturing Pharma Companies 324

Bio Pharma Dive

NOVEMBER 14, 2024

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Regulation 307

Regulation Drugs Marketing 307

Bio Pharma Dive

JANUARY 26, 2022

based Immunocore's treatment, known as Kimmtrak, is also the first T cell receptor drug to have reached market in the U.S.

Drugs 347

Drugs Marketing 347

Bio Pharma Dive

OCTOBER 6, 2022

A new fast track designation allows Lilly to begin the process of seeking approval of tirzepatide for obesity, though the drug will need to succeed in a second trial to get to market.

Drugs 336

Drugs Trials Marketing 336

Bio Pharma Dive

MAY 3, 2024

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

Drugs 289

Drugs Marketing 289

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs 278

Drugs Marketing 278

Pharmaceutical Technology

AUGUST 20, 2024

The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.

Marketing 263

Marketing Drugs 263

Bio Pharma Dive

APRIL 4, 2023

The first-line approval of Padcev together with Keytruda is viewed as important to expanding the drug’s market, and comes weeks after Pfizer agreed to buy Seagen for $43 billion.

FDA Approval 322

FDA Approval Drugs Marketing 322

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

Drugs 264

Drugs Marketing 264

Bio Pharma Dive

JULY 16, 2024

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs 284

Drugs Medicine Marketing 284

Bio Pharma Dive

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

Drugs 326

Drugs Marketing 326

Bio Pharma Dive

NOVEMBER 22, 2022

The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA.

Marketing 318

Marketing Drugs 318

Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval 284

FDA Approval Drugs Protein Marketing 284

Bio Pharma Dive

OCTOBER 17, 2022

Beginning a high-stakes advisory meeting, CDER head Patrizia Cavazzoni said that Covis Pharma’s drug is ineffective and should not remain on the market.

Drugs 292

Drugs Marketing 292

Bio Pharma Dive

JANUARY 19, 2023

“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

Marketing 336

Marketing Drugs 336

Bio Pharma Dive

DECEMBER 5, 2022

The positive results could help Novartis secure approval for earlier use of the radiopharmaceutical drug Pluvicto, potentially broadening the number of eligible patients by several times the current market.

Sales 301

Sales Drugs Marketing 301

Bio Pharma Dive

NOVEMBER 27, 2023

drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch. One year after the U.K.

Drugs 284

Drugs Trials Marketing 284

Pharmaceutical Technology

JULY 26, 2022

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Marketing 306

Marketing Gene Branding Clinical Development 306

Pharmaceutical Technology

JUNE 12, 2023

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

Marketing 242

Marketing Production Branding Manufacturing 242

Pharmaceutical Technology

JULY 25, 2022

Despite this, specialty generics are expected to be the domain of a handful of companies with the necessary manufacturing capabilities and legal backing needed for entering the market. Specialty drugs are most used to treat different cancers, rheumatoid arthritis, and multiple sclerosis. The only way forward for generics producers.

Drugs 298

Drugs Manufacturing Production Marketing 298

Pharmaceutical Technology

MARCH 17, 2023

These agreements have been particularly propelled by the recent rise in inflationary pressures and pharmaceutical market instability, pushing healthcare systems to find new ways to reduce risks associated with new drugs. Thus, a higher risk score reflects a more hostile market access environment and drug launch in a geographical area.

Marketing 257

Marketing Drugs Research Analyst Manufacturing 257

Pharmaceutical Technology

FEBRUARY 23, 2024

The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.

Generic Drugs 263

Generic Drugs Drugs Marketing 263

Pharmaceutical Technology

APRIL 3, 2023

The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilar Hyrimoz (adalimumab) citrate-free high-concentration formulation (HCF). With eight marketed biosimilars, Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe, with more than two decades of experience.

Marketing 264

Marketing Medicine Packaging Packaging 264

Pharmaceutical Technology

MARCH 29, 2023

In that trial, the drug demonstrated positive signs of clinical activity – all patients receiving VK2735 reported a loss in mean body weight. According to Sara Reci, analyst at GlobalData, many late-stage pipeline products for obesity emulate what is currently on the market, and employ the GLP-1 mechanism of action.

Drugs 264

Drugs In-Vivo Marketing Trials 264

Drug Patent Watch

MARCH 12, 2025

The Unseen Heroes of Generic Drugs: Stability Testing 101 As a consumer, have you ever stopped to think about the rigorous process that goes into bringing a generic version of your favorite medication to market? For generic drug manufacturers, stability testing is a critical step in the development process.

Generic Drugs 96

Generic Drugs Drugs Manufacturing Branding 96

Bio Pharma Dive

OCTOBER 25, 2022

Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.

Gene Therapy 293

Gene Therapy Sales Gene Marketing 293

Bio Pharma Dive

AUGUST 24, 2023

The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

Drugs 243

Drugs Manufacturing Marketing 243

Bio Pharma Dive

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 255

Marketing Drugs 255

Bio Pharma Dive

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Drugs 329

Drugs Marketing 329

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 5, 2024

The Subject Expert Committee (SEC) which advises the national drug regulator on drug approvals and clinical trials has recommended grant of permission to drug major Astrazeneca for import and marketing of two strengths of anti-hyperkalaemia therapy drug Lokelma (sodium zirconium cyclosilicate for oral suspension).

Clinical Trials 243

Clinical Trials Clinical Trials Drugs Regulation 243

Drug Patent Watch

JANUARY 30, 2025

Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. This exclusivity is a result of the patent protection granted to the drug's developer. Read the full article here: [link]

Marketing 54

Marketing Drugs Production Sales 54

Bio Pharma Dive

FEBRUARY 6, 2022

For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.

Drugs 364

Drugs Marketing 364

Bio Pharma Dive

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Drugs 343

Drugs Marketing 343

Bio Pharma Dive

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 313

Drug Trials Trials Drugs Marketing 313

Bio Pharma Dive

FEBRUARY 17, 2023

Apellis’ Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety.

FDA Approval 345

FDA Approval Drugs Marketing 345

Pharmaceutical Technology

NOVEMBER 6, 2024

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.

Marketing 263

Marketing Drugs 263